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ABSTRACT
Our previous preclinical studies and a Phase I clinical trial DP6-001 have indicated that a polyvalent Env
formulation was able to elicit broadly reactive antibody responses including low titer neutralizing
antibody responses against viral isolates of subtypes A, B, C and AE. In the current report, a panel of 62
gp120 immunogens were screened in a rabbit model to identify gp120 immunogens that can elicit
improved binding and neutralizing antibody responses and some of them can be included in the next
polyvalent formulation. Only about 19% of gp120 immunogens in this panel were able to elicit
neutralizing antibodies against greater than 50% of the viruses included in a high throughput PhenoSense
neutralization assay when these immuongens were tested as a DNA prime followed by a ﬁxed 5-valent
gp120 protein vaccine boost. The new polyvalent formulation, using ﬁve gp120 immunogens selected
from this subgroup, elicited improved quality of antibody responses in rabbits than the previous DP6-001
formulation. More signiﬁcantly, this new polyvalent formulation elicited higher antibody responses against
a panel of gp70V1/V2 antigens expressing V1/V2 sequences from diverse subtypes. Bioinformatics analysis
supports the design of a 4-valent or 5-valent formulation using gp120 immunogens from this screening
study to achieve a broad coverage against 16 HIV-1 subtypes.
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Introduction
After close to three decades’ effort, it is becoming clear that the
heterologous prime-boost vaccination approach is the one show-
ing the greatest promise among a long list of vaccination
approaches tested for HIV vaccine development. RV144 trial using
an ALVAC vector prime and recombinant gp120 protein boost is
the only trial of an HIV vaccine where a modest reduction in the
risk of HIV acquisition was observed.1 Almost at the same time, a
Phase I clinical trial DP6-001 conducted in healthy adult volun-
teers, using the DNA prime- recombinant gp120 protein boost
strategy developed by our team, showed robust immunogenicity
including 100% response rate of high level HIV-1 antigen speciﬁc
antibody and T cell immune responses.2,3 Sera from immunized
human sera had low titer neutralizing antibody responses against
relatively difﬁcult to neutralize viruses from subtypes A, B, C and
E although the Nab titers were poor against the standard Tier 2
viral isolates.2 It is possible that DP6-001 formulation using a poly-
valent Env formulation in both DNA prime and protein boost
immunizations was able to elicit broad antibody responses con-
ﬁrming ﬁndings from our preclinical study that the polyvalent for-
mulations were more effective than monovalent formulations in
eliciting broader neutralizing antibody responses.4
However, ﬁve gp120 immunogens included in DP6-001
were randomly selected based on the available Env sequences
from primary HIV-1 isolated in the mid-1990s. With more
primary HIV-1 Env sequences available in the last 10–15 years,
it is an important question to understand whether these Env
proteins have the same level of immunogenicity in eliciting
antibody responses, especially the ability to elicit neutralizing
antibody responses, and such information can guide the ratio-
nal selection of next generation polyvalent Env formulations.
In the current study, we ﬁrst conducted a high-throughput
immunogenicity study in the rabbit model to compare the abili-
ties of individual gp120 immunogens delivered in the form of
DNA vaccines to elicit neutralizing antibody responses when the
DNA-immunized animals received a ﬁxed protein boost which
includes ﬁve recombinant gp120 proteins. Our previous studies
have demonstrated that recombinant Env proteins alone are not
effective in eliciting reliable neutralizing antibodies yet the inclu-
sion of a DNA priming step was able to greatly enhance the
immunogenicity of Env proteins to elicit improved Nab.5-8
Our data indicated not every gp120 has the same immuno-
genicity and only about 10–15% Env was capable of eliciting
immune sera neutralizing more than 50% viral isolates in a
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study panel. Based on this analysis, a new polyvalent Env for-
mulation was produced consisting of ﬁve new gp120 immuno-
gens selected from the current screening study. This new
polyvalent gp120 formulation showed enhanced potency and
improved breadth of antibody responses, in comparison with
the previous DP6-001 polyvalent formulation. The new polyva-
lent gp120 formulation was also able to elicit broader anti-V2
antibody responses which may be involved in ADCC functions.
Data presented in this report support the production and test-
ing of the next generation polyvalent Env formulation in a
human study.
Result
Immunogenicity testing of a panel of 62 gp120 DNA
vaccines in a DNA prime-protein boost design to produce
immune rabbit sera for neutralizing activity analysis
In our previous DP6-001 Phase I clinical study in healthy adult
volunteers, the polyvalent Env formulation delivered by the
DNA prime-protein boost approach was highly immunogenic
including the potent and broadly cross reactive Env-speciﬁc
antibody responses in 100% of the volunteers based on solid
phase antibody assays including ELISA and Western Blot anal-
yses.2 Furthermore, immune sera from this study demonstrated
weak neutralizing antibody responses in a high-throughput
TZM-bl neutralization assay against a diverse panel of primary
HIV-1 isolates from subtypes A, B, C and AE which are not
easy to neutralize.9-11 However, the titers of Nab activities were
relatively low against this panel of primary viruses and the
same set of human immune sera was not able to neutralize the
standard Tier 2 viruses.2
In the current study, we investigated the possibility of using
a new polyvalent Env formulation to generate improved protec-
tive antibody responses. The original DP6-001 formulation
included four primary gp120 immunogens (92UG037.8 of sub-
type A, 92US715.6 of subtype B, 96ZM651 of subtype C and
93TH976.17 of subtype AE) and one TCLA gp120 immunogen
(Bal) (Supplement Table 1). They were included in the DP6-
001 formulation randomly because there were limited intact
gp120 molecular clones available at the time. In contrast, the
current study included 62 HIV-1 gp120 immunogens covering
subtypes A, B, C, D, F, G and CRF01_AE (AE) including one
consensus AE (Table 1). These Env sequences were originally
cloned from HV-1 infected patients in various geographic
regions including Africa, North America, South America,
Europe and Asia and from different tissues including plasma,
PBMCs, lymph nodes, and brains9,10,12-27 (Table 1). The num-
ber of gp120 immunogens included in this panel is not same
among different subtypes because several rare subtypes have
less available molecular clones than other subtypes. More
importantly, it is recognized that HIV genotypes could not well
predict the neutralizing antibody subtypes.28
Because the central objective of the current study is to screen
among a large panel of gp120 immunogens and understand
whether any particular gp120 has improved ability in eliciting
antibody responses than the previous DP6-001 formulation,
the study was designed to focus on gp120 immunogens with
such potential. Individual gp120 sequences were cloned into
the same DNA vaccine vector pJW4303 and used as the prim-
ing vaccine in a standard DNA prime-protein boost strategy in
rabbits (Fig. 1), which we have shown to be superior to DNA
or protein immunization alone.2,4-8,29 The reason to include a
ﬁxed 5-gp120 protein as the boost has multiple considerations:
1) it will take signiﬁcant time and resources to produce over 60
Table 1. List of the original HIV-1 viruses from which gp120 DNA vaccines were
produced.
Envelope of
HIV-1 strains Subtype
Tissue of
Isolation Origins GenBank# Reference
92RW020.5 A PBMC Rwanda U08794 12
92UG037.8 A PBMC Uganda U09127 12
CA1 A PBMC Cameroon X80438 21
NA20-B27 B Brain UK NA 13
NA420-LN85 B Lymph node UK NA 13
NA420-B42 B Brain UK NA 13
NA118-B12 B Brain UK NA 13
NA118-LN27 B Lymph node UK NA 13
NA20-B76 B Brain UK NA 13
NA20-B59 B Brain UK NA 13
NA420-LN40 B Lymph Node UK NA 13
P6B33 B Brain UK NA 13
6101LN B PBMC USA AY835434 9
5768.04 B PBMC US AY835435 9
QH0692.42 B PBMC Trinidad AY835439 9
QH0515.01 B PBMC Trinidad AY835440 9
SS1196.01 B PBMC US AY835442 9
BG1168.01 B PBMC US AY835443 9
PVO-04 B PBMC Italy AY835444 9
AC10.0.29 B PBMC US AY835446 9
92US715.6 B PBMC USA U08451 12
AC10.44 B PBMC UK NA 23
Yu-2 B Brain USA M93258 20
89.6 B PBMC USA M96155 15
JR-FL B Brain USA HIVU63632 20
Ba-L B Lung USA JQ715387 20,22
H78639 B PBMC USA NA 16
ADA B PBMC USA AY426119 24
AD8 B PBMC USA AF004394 25
6535.3 B PBMC USA AY835438 9
REJ4541.67 B Plas ma USA AY835449 9
RHPA4259.7 B Plas ma USA AY835447 9
CAAN5352 B Plas ma USA AY835452 9
WITO4561 B Plas ma USA AY835451 9
TRO.11 B PBMC Italy AY835445 9
SC422661.8 B Plas ma Trinidad AY835441 9
TRJO4551.58 B Plas ma USA AY835450 9
THRO4156.18 B Plas ma USA AY835448 9
SF162 B CSF USA EU123924 20
Du123.6 C PBMC S. Africa DQ411850 10
Du156.12 C PBMC S. Africa DQ41185 10
93MW965.26 C PBMC Malawi U08455 12
92BR025.9 C PBMC Brazil U09126 12
96ZM651.2 C PBMC Zambia AF286224.1 26
96BW01B22 C PBMC Bots wana AF110961 27
96BW15C02 C PBMC Bots wana AF110974 27
CAP45.2 C Plas ma S. Africa DQ435682 10
DU172.17 C PBMC S. Africa DQ411853 10
DU422.1 C PBMC S. Africa DQ411854 10
ZM214M.PL15 C Plas ma Zambia DQ388516 10
ZM109F.PB4 C PBMC Zambia DQ388514 10
CAP210.2 C Plas ma S. Africa DQ435683 10
ZM53M.PB12 C PBMC Zambia AY423984 10
ZM135.PL10a C Plas ma Zambia AY42407 10
ZM197M.PB7 C PBMC Zambia DQ388515 10
ZM233M.PB6 C PBMC Zambia DQ388517 10
ZM249M.PL1 C Plas ma Zambia DQ388514 10
92UG021.16 D PBMC Uganda U27399 12
93TH976.17 CRF01_AE PBMC Thailand U08458 12
AE-Cons CRF01_AE NA NA NA NA
93BR020.17 F1 PBMC Brazil U27401 12
92UG975.10 G PBMC Uganda U27426 12
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individual recombinant gp120 proteins, and the variation on
the quality and purity of these proteins may further impact the
immunogenicity results; and 2) a polyvalent Env formulation is
more capable to expand the breadth of antibody responses than
a single Env protein boost. A polyvalent Env formulation may
also minimize the bias if only one ﬁxed protein is used as the
boost. The inclusion of these ﬁve gp120 proteins in the boost
was based on the availability of highly puriﬁed quality and a
large quantity supply.
New Zealand White (NZW) rabbits were ﬁrst immunized by
one of 62 individual DNA vaccines three times by a gene gun
followed by two boost immunizations with a ﬁxed 5-gp120 pro-
tein mix (UG21-9, 92US715.6, JR-FL, TH14-12 and 93MW959)
delivered subcutaneously along with the Incomplete Freund’s
Adjuvant (IFA). IFA was used in the current study because it
was used in previous published studies from our group so the
data from the current study can be compared with the previous
data. Sera were collected before immunization and after either
DNA prime or protein boost. The neutralizing antibody analy-
sis was done by a high throughput commercial “PhenoSense
Assay” which included a target panel of 13 primary viral iso-
lates (92RW020 and 94UG103 of subtype A, AC10.0.29,
PVO.4, QH0692.42, SC422661.8, and JRCSF of subtype B,
93IN905 and 98CN006 of subtype C, 92UG046 and 94UG114
of subtype D, and 92TH021 and CMU02 of subtype AE) and 3
TCLA strains (MN, NL43 and SF162).
Neutralizing activities of immune rabbit sera elicited with
different gp120 DNA prime
Among 62 gp120 immunogens tested in this single DNA prime
and 5-valent gp120 protein boost standard design, they can be
divided into three subgroups based on the breadth of neutraliz-
ing activities (Table 2). The ﬁrst subgroup of 12 gp120 immu-
nogens (about 19.3% of this group) elicited rabbit immune sera
neutralized more than 50% of the viral isolates in this testing
panel, albeit at low titers. The second subgroup of 10 (16.1%)
neutralized between a quarter to up to one half of the viral iso-
lates (25–49%). The remaining 40 (64.5%) gp120 immunogens
elicited much narrow neutralizing activities (6–24% of the viral
isolates).
Figure 1. The rabbit immunization and serum collection schedules for individual
gp120 immunogen screening study.
Table 2. The neutralizing antibody breadth induced by various gp120 DNA vaccine
prime in rabbits.
Envelope Subtype No. of PV neutralized % of PV neutralized
WITO4561 B 1 6%
NA420-B42 B 2 13%
QH0515.01 B 2 13%
PVO-04 B 2 13%
REJ4541.67 B 2 13%
TRO.11 B 2 13%
TRJO4551 B 2 13%
THRO4156 B 2 13%
ADA B 3 19%
NA420-LN85 B 3 19%
NA118-B12 B 3 19%
P6B33 B 3 19%
QH0692.42 B 3 19%
BG1168.01 B 3 19%
Yu-2 B 3 19%
Ba-L B 3 19%
H78639 B 3 19%
AD8 B 4 25%
AC10.0.29 B 4 25%
89.6 B 5 31%
RHPA4259 B 5 31%
CAAN5352 B 5 31%
SC422661.8 B 5 31%
SF162 B 5 31%
5768.04 B 6 38%
SS1196.01 B 6 38%
NA420-LN40 B 6 38%
92US715.6 B 8 50%
NA118-LN27 B 9 56%
AC10.44 B 9 56%
6535.3 B 10 63%
NA20-B59 B 11 69%
6101LN B 12 75%
NA20-B27 B 13 81%
NA20-B76 B 14 88%
JR-FL B 14 88%
92RW020.5 A 1 6%
CA1 A 2 13%
92UG037.8 A 7 44%
Du123-06 C 2 13%
92BR025.9 C 2 13%
96ZM651.2 C 2 13%
ZM53M.PB12 C 2 13%
ZM135M.PL10a C 2 13%
ZM233M.PB6 C 2 13%
Du156-12 C 3 19%
96BW01B22 C 3 19%
96BW15C02 C 3 19%
DU422.1 C 3 19%
ZM214M.PL15 C 3 19%
ZM109F.PB4 C 3 19%
CAP210.2 C 3 19%
ZM197M.PB7 C 3 19%
ZM249M.PL1 C 3 19%
CAP45.2 C 4 25%
DU172.17 C 4 25%
93MW965.26 C 15 94%
92UG021.16 D 14 88%
93TH976.17 A/E 2 13%
AE-cons A/E 8 50%
93BR020.17 F1 7 44%
92UG975.10 G 3 19%
This panel of pseudoviruses (PV) included three TCLA strains (MN, NL43 and
SF162), and 13 primary isolates from subtype A (92RW020, 94UG103), B
(AC10.0.29, PVO.4, QH0692.42, SC422661.8, JRCSF), C (93IN905, 98CN006), D
(92UG046, 94UG114), and AE (92TH021, CMU02). Based on the % PV neutralized,
there are three subgroups: the red highlighted (12 gp120 immunogens, 19%) is
the subgroup with broad NAb (>D 50% of PV neutralized: the yellow highlight
(10 gp120 immunogens, 16%) is the subgroup with moderate NAb (25–49% of
PV neutralized); and remaining (40 gp120 immunogens, 65%) is the subgroup
with narrow NAb (< 24% of PV neutralized).
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To evaluate whether stronger neutralizing antibody
responses correlated with higher binding antibody responses,
titers of gp120-speciﬁc antibody responses for the above three
subgroups were measured. Overall there was no signiﬁcant dif-
ference in titers of binding antibody responses among three
neutralization subgroups (Fig. 2). Therefore, gp120 immuno-
gens in the best neutralizing antibody subgroup did not elicit
unusually higher antibody responses than gp120 immunogens
in other subgroups, and the level of binding antibody responses
was not responsible for neutralizing antibody responses.
The gp120 immunogens that were best able to elicit Nab
responses are from different subtypes and do not appear to be
clustered closely based on the gene sequence analysis (Fig. 3).
The neutralizing antibody proﬁle was further analyzed for its
relationship to the sources of gp120 immunogens (Fig. 4). In
the best Nab subgroup, there are similar numbers of gp120
Figure 2. The gp120-speciﬁc antibody titers as measured by ELISA. Rabbit sera
from individual gp120 screening study were tested against the ﬁxed ﬁve gp120
proteins use in the boost. The end titration titers shown are the averages with
standard deviation of each neutralization subgroup (narrow, moderate or broad).
Figure 3. The phylogenetic tree analysis of the amino acid sequences of 62 gp120 DNA immunogens included in the screening study. The arrows indicate those gp120
immunogens in the broad NAb subgroup.
HUMAN VACCINES & IMMUNOTHERAPEUTICS 2999
immunogens from all four major tissue sources (plasma, brain,
PBMC and lymph node), with no indication that any particular
source may be responsible for the improved breadth of Nab
responses. When different sources are analyzed, PBMC repre-
sented a higher percentage of gp120 immunogens (60%) in
both moderate and narrow Nab subgroups. But this may only
reﬂect the fact that the PBMC source gp120 immunogens are
the majority of gp120 immunogens included in the current
study (Table 1). On the other hand, most of brain source and
lymph node source gp120 immunogens in the current study
are found in the best Nab subgroup (Fig. 4). Due to the small
sample size, this observation will need future studies to estab-
lish any true correlation.
The V1/V2 loop of HIV-1 Env proteins is the region with
the highest sequence variation including the length of V1/V2 as
previously published.30 Lengths of the V1 and V2 loops among
the gp120 did not correlate with breadth of neutralization
(supplement Fig. 1).
Antibody responses elicited with the new 5-valent gp120
DNA prime-protein boost formulation
Next, the new polyvalent vaccine was formulated with ﬁve
gp120 immunogens selected from the broad Nab group to
examine whether the new formulation is able to elicit better
neutralizing antibody responses than the previous DP6-001 for-
mulation. One gp120 immunogen from each of ﬁve major sub-
types (subtypes A, B, C, D and AE) was selected from the broad
Nab group (Table 3) to expand the coverage of HIV-1 viral Env
spectrum. The preliminary antigenicity analysis using ELISA
with four representative mAbs demonstrated that these ﬁve
gp120 immunogens preserved broad epitopes such as those rec-
ognized by the CD4bs mAb VRC-01, glycan speciﬁc mAbs
2G21 and PGT128. The subtype AE gp120 immunogen even
showed good binding by PG9, a well-known trimer speciﬁc
mAb PG9. The overall high levels of binding were observed
except subtype D gp120 immunogen which had much lower
binging with VRC-01 and PGT128 (Fig. 5).
The more complete binding afﬁnities of these ﬁve gp120
immunogens were measured with a bigger panel of gp120-
speciﬁc human and rabbit mAbs covering a wide range of
epitopes (including C1, C2, C5, V2, V3, CD4bs and glycan)
and the IgG-CD4 fusion protein, showing an overall high level
of binding afﬁnities (Table 4) except a few epitopes on gp120
Figure 4. The tissue sources of gp120 immunogens identiﬁed in different Nab sub-
groups. The numbers shown are percentages of each source in a particular sub-
group. The sum of all sources within one subgroup equals to 100%. The statistical
signiﬁcance is calculated using Fisher exact test for the difference of one source
between broad and moderate subgroups, or between broad and narrow sub-
groups, # indicating p < 0.01 and  indicating p < 0.05.
Table 3. New 5-valent gp120 immunogens.
Immunogen Subtype HIV-1 isolate
gp120-A2 A 92UG037.8
gp120-JRFL B JR-FL
gp120-C2 C 93MW965.26
gp120-D D 92UG021.16
gp120-AE CRF01_AE NA (Consensus)
Figure 5. The antigenicity analysis (binding antibody) of the 5 gp120 immunogens included in the new polyvalent formulation by gp120-speciﬁc bnAbs VRC01, 2G12,
PG9 and PGT128 in serial dilutions. ELISA was run with individual gp120 proteins (A2, JR-FL, C2, D or AE con) coated on the microtiter plates as indicated. Curves are
shown as the average of two duplicate wells.
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immunogen from subtypes D which is not unexpected given
the signiﬁcant difference between subtype D and other HIV-
1 M group subtypes.
The relative immunogenicity between DP6-001 and the
new 5-valent was compared in rabbits using the standard
three-time DNA immunizations followed with twice protein
immunizations using the matched ﬁve gp120 immunogens.
The levels of gp120-speciﬁc binding antibodies as measured
by standard ELISA were very similar between two polyva-
lent formulations. Both formulations are highly immuno-
genic in eliciting high titer gp120-speciﬁc IgG responses
(Fig. 6a). However, further studies identiﬁed the difference
in quality of antibody responses. Our previous studies in
rabbits and human trial demonstrated that the DNA prime-
protein boost approach is capable of eliciting CD4bs anti-
bodies. In the current study, the new polyvalent formulation
was able to induce higher levels of CD4bs antibody
responses than the previous DP6-001 formulation based on
the competition of CD4bs mAb b12 (Fig. 6b).
The neutralizing activities of rabbit immune sera were ana-
lyzed by two different types of assays. The ﬁrst is the high
throughput commercial PhenoSense assay by Monogram. Indi-
vidual serum titration curves showed an upward shift of new
polyvalent rabbit sera when compared with that of the DP6-
001 sera against 5 viruses in this assay (Fig. 7a). The second
neutralization study was conducted by the TZM-bl assay con-
ducted at Duke University. Two Tier 1A TCLA and four Tier 2
viruses were included in the TZM-bl assay. In both assays, the
neutralizing activities of the new polyvalent Env formulation
rabbit sera were clearly higher than the rabbit sera elicited by
the DP6-001 formulation (Fig. 7).
An additional neutralization assay was conducted against a
panel of selected viruses including those from different stan-
dard tiers (Fig. 8). At 1:10 serum dilution, rabbit sera elicited
by the new polyvalent formulation neutralized about 40% of
viruses in this panel while the previous DP6-001 vaccine rabbit
sera neutralized only slightly above 20% of viruses.
The proﬁle of epitope-speciﬁc antibody responses in rabbit
sera elicited by the new polyvalent formulation was analyzed by
peptide array binding. It showed a pattern of antibody responses
against epitopes spreading to all constant and variable domains
including the V2 domain in multiple gp120 immunogens
(Fig. 9). Further detailed analysis was done using the gp70V1/V2
chimeric antigen system expressing V1/V2 domains from gp120
immunogens included in both DP6-001 and the new polyvalent
formulations. Sera elicited by the new polyvalent formulation had
higher antibody responses against this group of gp70V1/V2 anti-
gens than the sera elicited by DP6-001 formulation (Fig. 10).
Because ADCC activities against V2 region was found to be an
immune correlate of protection in RV144 studies, the ability of
new 5-valent formulation to elicit higher antibody responses
against diverse V1/V2 immunogens is highly signiﬁcant.
The current study further supports the value of an improved
polyvalent gp120 formulation. Because of the extremely high
mutation rate of HIV-1 viruses, it has been one of the key chal-
lenges in developing an HIV vaccine that can cover enough
breadth of circulating HIV viral isolates. We used a bioinfor-
matics model to see the impact of polyvalency to the coverage
Table 4. Antigenicity analysis of new 5-vlaent gp120 immunogens.
Octet Qke binding afﬁnity (KD(M))
mAb Epitope Host gp120-A gp120-B gp120-C gp120-D gp120-AE
IgG-CD4 CD4bs human 2.56E-09 6.40E-09 1.12E-07 NB 1.84E-08
VRC01 CD4bs human 1.73E-09 1.4–09 2.29E-08 NB 5.45E-09
PGT128 Glycan human 6.96E-10 2.10E-09 2.03E-08 ND 1.72E-08
2G12 Glycan human 1.36E-10 <1E10-12 7.38E-10 2.00E-10 4.64E-10
2158 V2 human 6.46E-09 3.26E-09 2.46E-08 ND 3.05E-08
R15 C1 rabbit 1.97E-09 9.92E-10 1.22E-08 1.97E-09 1.38E-09
R20 V3 rabbit 2.48E-09 9.25E-11 8.58E-07 2.48E-09 1.99E-09
R53 C4 rabbit 1.54E-09 1.97E-09 3.98E-09 1.79E-09 2.49E-09
R13 C5 rabbit 1.89E-09 4.36E-10 1.23E-08 1.68E-09 4.01E-09
NB – no binding; ND– not done.
Figure 6. Analyses of antibody responses in rabbit immune sera elicited by either DP6-001 or the new polyvalent formulation. (A) The gp120-speciﬁc antibody titers were
measured by ELISA against the autologous 5 gp120 proteins included in either DP6-001 or new polyvalent formulation. (B) The ability of rabbit sera to outcompete bind-
ing of CD4bs-speciﬁc mAb b12 to JR-FL & VSV-G pseudotyped viruses. Competition titer is deﬁned as the serum dilution preventing 50% of pseudoviral binding to the
ELISA plate. The statistical analysis was done with t-test.
HUMAN VACCINES & IMMUNOTHERAPEUTICS 3001
of circulating HIV-1 isolates (Fig. 11). In this model, the
sequence homology was analyzed between gp120 sequences
included in a polyvalent formulation and the consensus
sequences from each of the 16 key subtypes of HIV-1 M group.
The heat map method was used to show the level of homology.
It is clear that the homology is very low when only one gp120
immunogen is tested – only the matching subtype shows some
degree of homology but not to any other subtypes. When
the valency is increased from two-valent to ﬁve-valent, the
homology increased to over 90% to any subtype. Actually, even
four-valent formulation is already able to achieve high homol-
ogy, especially the one without the subtype D (ACBCCCAE).
The results from the bioinformatics model and the neutralizing
data reported here provide the direction for future HIV vaccine
development.
Discussion
In the last three decades, HIV vaccine development has put
major emphasis on the optimal vaccine delivery approaches
Figure 7. Neutralizing activity in rabbit sera elicited by ether DP6-001 and new polyvalent formulation. (A) Percent of inhibition by rabbit immune sera in the PhenoSense
assay. Each curve represent serum from one rabbit. (B) Neutralizing titers in rabbit immune sera as tested by TZM-bl assays. Five rabbit sera were tested for each formula-
tion. The mean titers with standard deviations are shown. NAb titer is deﬁned as the serum dilution capable of inhibiting 50% of viral infection. Rabbit sera collected two
weeks after the ﬁnal boost immunization were tested for their ability to neutralize various viruses. The statistical signiﬁcance (p < 0.05) is indicated with “”, using one
way ANOVA.
Figure 8. Neutralizing breadth of rabbit sera elicited by DP6-001 and new 5-valent gp120 vaccines against a panel of 26 HIV-1 pseudoviruses as shown in TZM-bl assay.
The percentage of virus neutralized was calculated based on the positive neutralization events of 5 rabbits/each group against 26 viruses. The positive NAb is deﬁned as
the serum capable of inhibitingD />50% of viral infection at >D 1:10 serum dilution. The statistical signiﬁcance is indicated and analyzed using Fisher exact test. Rabbit
sera collected two weeks after the ﬁnal boost immunization were used for the assay.
3002 S. WANG ET AL.
and the induction of broad neutralizing antibody responses.
The unexpected protection results of RV144 trial suggested the
heterologous gene-based vaccine prime and recombinant
protein vaccine boost offers an alternative approach based on
non-neutralizing antibodies. An improved polyvalent Env for-
mulation offers potential value in augmenting the protection
afforded in RV144 which only included Env immunogens from
two subtypes. Our early rabbit immunogenicity study showed
that randomly selected polyvalent gp120 formulations were
able to elicit statistically signiﬁcant higher neutralizing antibody
responses in rabbit immune sera than any of the individual
gp120 immunogens included in those polyvalent formulations.4
The 5-valent DP6-001 formulation tested in a subsequent
Phase I human clinical study elicited broadly reactive antibody
responses against gp120 antigens from subtypes A to G and
low titer but broad neutralizing antibody responses in a high
throughput PhenoSense assay.2 Recently, ALVAC/Pentavalent
gp120 protein (B/E/E/E/E) vaccine with increased diversity of
gp120 motifs in the immunogen elicited a broader antibody
response and enhanced protection in a SHIV challenge model
in macaques,31 supporting the importance to develop polyva-
lent HIV-1 vaccines.
In the current study, we investigated the possibility to fur-
ther improve the quality of antibody responses based on the
Figure 9. Evaluation of serum antibodies binding in new 5-valent vaccine immunized rabbit to linear peptides spanning gp120 antigens by JPT peptide microarray. The
peptides were 15-mer with 11-overlap. The peptide panels A, B, C, D and E represent autologous immunogens in the new 5-valent vaccine: 92UG037.8 (subtype A), JR-FL
(subtype B), 93MW965.26 (subtype C), 92UG021.16 (Subtype D), and AE consensus (CRF_01 AE). Peptide panel M is the Group M consensus sequence. The peptide panels
LN40 and B33 are two additional subtype B viruses. The signal intensities were the group mean of the normalized values with pre-bleed background subtracted. Rabbit
sera collected two weeks after the ﬁnal boost immunization were used for peptide microarray assay.
Figure 10. ELISA analysis of gp70V1/V2-speciﬁc antibody responses in rabbit sera induced by either DP6-001 (Panel A) or the new 5-valent vaccines (Panel B). Ten individ-
ual gp70V1/V2 scaffold proteins were used as coating antigens covering subtypes A, B, C, D and AE. The gp70V1/V2 antigens autologous to the DP6-001 were A2
(92UG037.8, subtype A), US715 (92US715.6, subtype B), Ba-L (subtype B), Czm (96ZM9651, subtype C) and AE (93TH967, CRF_01 AE). The gp70V1/V2 antigens autologous
to the new 5-valent were A2 (92UG037.1, subtype A), JR-FL (subtype B), C2 (93MW965.26, subtype C), D (92UG021.16 Subtype D) and AE-con (AE consensus, CRF_01 AE).
The Case-A2 gp70V1/V2 is a commonly used subtype B antigen as the reference control. The empty gp70 vector was used as the negative control. Rabbit sera collected
two weeks after the ﬁnal boost immunization were used in this study. Each curve represents one rabbit serum from each immunogen group against one gp70V1/V2 anti-
gen. Panel C shows the mean antibody titers between A and B with statistical signiﬁcance indicated using the t-test.
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optimal selection of gp120 immunogens in a new polyvalent
formulation, Several important pieces of information were
learned. First, it appears that not all the gp120 immunogens are
created equal in their ability to elicit high quality antibody
responses as measured by neutralizing activities. Second, the
new polyvalent formulation with selected gp120 immunogens
was able to elicit better neutralization antibodies than the origi-
nal DP6-001 which was randomly formulated. While the sera
elicited by the new polyvalent formulation still could not neu-
tralize the standard Tier 2 panel of viral isolates, the improve-
ment on neutralizing antibodies against other viruses was clear
including both breadth and potency of Nab using the sera eli-
cited by DP6-001 as the control. Third, the new polyvalent for-
mulation was also able to elicit higher antibody responses
against a diverse group of gp70V1/V2 antigens. As we learned
from RV144 trial, ADCC mediated through V2 epitopes may
correlate to the protection efﬁcacy.32 It is possible that a better
gp120 immunogen may have the structure features that are
beneﬁcial to the induction of both Nab and ADCC responses.
IgA may affect ADCC as learned from RV144 but there are
many IgA subtypes in rabbit which makes the measurement of
rabbit IgA more difﬁcult.33 Future human studies are needed to
establish the improvement of ADCC with the new polyvalent
formulation.
The current study was unable to identify the exact factors
contributing to those 19% gp120 immunogens that are able to
prime the immune system to elicit better neutralizing antibody
responses. It is possible that the tissue sources from which the
original HIV-1 primary viruses were isolated may play a role
because gp120 immunogens isolated from the brain and lymph
are mainly discovered from this subgroup. It was reported in
literature that HIV-1 viruses isolated from different tissues may
have differences in target cell type preference (T cell tropic vs.
macrophage tropic), afﬁnity to CD4 and sensitivity to different
neutralizing mAbs.34-36 We further observed that a pair of two
primary gp120 immunogens isolated from the same patients
with high sequence homology but different CD4 afﬁnity and
proﬁle of Nab mAb sensitivity showed different immunogenic-
ity in eliciting Nab responses.37 Future studies need to under-
stand the impact of tissue sources to the selection of viral Env
Figure 11. Bioinformatics analysis on the coverage between various gp120 immunogen formulations and the consensus sequences of HIV-1 subtypes. The A, B, C, D and
AE indicated at the left represent the new 5-valent gp120 immunogens: 92UG037.8 (subtype A), JR-FL (subtype B), 93MW965.26(subtype C), 92UG021.16 Subtype D), and
AE consensus (CRF_01 AE). Sixteen HIV-1 subtypes are indicated on the top, representing the consensus sequences of each subtype. Heat map analysis was used to indi-
cate the level of coverage, with warmer color indicating higher levels of coverage. Numbers indicated at the bottom of heat map are the percentages of sequence cover-
age between the ﬁve-valent gp120 formulation and 16 different subtypes.
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products for viral ﬁtness and/or structure modiﬁcations such as
type of glycosylation.
The bioinformatics model analysis conducted in the current
report pointed to the theoretical basis for a polyvalent Env HIV
vaccine. While the current analysis is oversimpliﬁed by using a
consensus gp120 sequence to represent a full subtype of gp120
sequences, the collection of 16 consensus gp120 sequences does
cover the diverse scope of HIV-1 gp120 immunogens. It is quite
interesting to see that the coverage by the new 5-valent gp120
formulation against these 16 HIV-1 subtypes can reach greater
than 90. However, the sequence homology between any one of
these ﬁve gp120 immunogens to these 16 subtype consensus
gp120 sequences was very low unless to its autologous subtype.
With the increase on the numbers of gp120 immunogens in a
formulation, the coverage to 16 subtypes was improved. These
data validated the polyvalent formulation as a key principle in
vaccinology and provided strong argument to the use of poly-
valent formulation design even to a highly mutated pathogen
like HIV-1. A number of recent studies also demonstrated
the effectiveness of polyvalent Env formulations even such for-
mulations only including multiple Env immunogens from 1–2
subtypes.31,38
The bioinformatics analysis also showed that if subtype
D is not considered a major target viral subtype, then the
four-valent formulation including four gp120 immunogens
selected from the current study will also achieve a very high
percentage of coverage against different subtypes. A clinical
formulation based on these four gp120 immunogens (sub-
types A, B, C and AE) has been successfully produced from
CHO cells under GMP and is scheduled to be tested as a
matched polyvalent DNA prime – protein boost vaccine in
a clinical trial to be run by the HIV Vaccine Trial Network
(HVTN). Data from future clinical studies will further vali-
date the ﬁndings learned from the current rabbit immuno-
genicity study.
Materials and methods
DNA vaccines
Sixty-two individual plasmid DNA vaccines expressing HIV-1
gp120 proteins from subtypes A, B, C, D, AE, F and G (Table 1)
were constructed utilizing the same vector pJW4303 at NheI
and BamHI sites under the tPA leader.39 The expression of
gp120 proteins from each individual DNA vaccine was veriﬁed
by transient transfection of 293T cells and Western blot analy-
sis as previously described.4 The DNA vaccines were puriﬁed
using QIAGEN Mega DNA prep kit (Valencia, CA) for rabbit
immunization studies.
Recombinant gp120 proteins
Nine recombinant gp120 proteins, HIV-1 subtypes A
(92UG037.8, UG21-9), B (92US715.6, JR-FL, TH14-12),
C (93MW959, 93MW965.26), D (92UG021.16) and AE (con-
sensus) (Supplement Table 1), included in the current study
were produced from stably transfected CHO cell lines as previ-
ously described.2,4 CHO cell cultures were harvested and gp120
proteins were puriﬁed over a lectin column, and further
polished by the ion-exchange and size-exclusion chromatogra-
phy as needed. The quality of puriﬁed gp120 proteins was veri-
ﬁed by SDS-PAGE and Western blot analysis. These gp120
proteins were used as the protein boost immunizations in rab-
bit studies, and as antigens to evaluate the Env-speciﬁc anti-
body responses by ELISA, and the binding afﬁnity analysis by
using the forteBio Octet QKe system.
gp70V1/V2 scaffold proteins
Nine recombinant gp70V1/V2 proteins were generated in the
current study. The V1/V2 regions from HIV-1 subtypes A
(92UG037.8), B (92US715.6, JR-FL, Case-A2), C (96ZM965,
93MW965.26), D (92UG021.16) and AE (93TH967, consensus)
was individually PCR-ampliﬁed from relevant gp120 DNA vac-
cines, and subcloned into the mammalian expression vector
pJW4303 containing the MLV gp70 backbone40 at the KpnI
and BamHI cloning sites. The V1/V2 was fused at the C-termi-
nal of the gp70 protein with a 6xHis tag at N-terminus of the
fusion protein. After DNA sequencing veriﬁcation of the con-
struct and large DNA prep using QIAGEN kit, the 293T cells
were transfected with each gp70V1/V2 plasmid DNA to express
the gp70V1/V2 proteins. The transfected 293T cell supernatant
was harvested at 72 hours after the transfection and gp70V1/
V2 proteins were puriﬁed by using a nickel afﬁnity column.
The purity of gp70V1/V2 proteins were veriﬁed by SDS-PAGE
and their reactivity was analyzed by Western-blot analysis using
a homemade anti-V1/V2 polyclonal rabbit serum.
Env-speciﬁc antibodies
The CD4 binding site speciﬁc monoclonal antibody, VRC01,41
was obtained from the AIDS Research & Reference Reagent
Program. The glycan speciﬁc mAb PGT12842 was provided by
International AIDS Vaccine Initiative (IAVI) and the V2 qua-
ternary mAb PG943 was provided as a gift from Dr. Dennis
Burton at Scripps Institute. The glycan mAb, 2G12,44 were
purchased from Polymun (Klosterneuburg, Austria). The V2-
speciﬁc mAb 215845 was produced by Dr. Susan Zolla-Pazner’s
group at Mount Sinai School of Medicine. The rabbit mAbs
R15 (C1), R20 (V3), R53 (C4) and R13 (C5) were generated in-
house from gp120 immunized rabbit.46,47
Rabbit immunization
New Zealand White (NZW) rabbits of 6–8 weeks’ old were
used in the current study with two DNA prime-protein
boost study designs. The rabbits were purchased from Harlan
Laboratories (Indianapolis, IN) and housed in the animal
facility managed by the Department of Animal Medicine at the
University of Massachusetts Medical School (UMMS) in
accordance of the protocol approved by UMMS’ Institutional
Animal Care and Use Committee (IACUC).
In the ﬁrst gp120 antigen screening study, each rabbit
received one individual DNA vaccine prime followed by a ﬁxed
ﬁve gp120 protein mix boost consisting of gp120 proteins from
HIV-1 subtypes A (UG21-9), B (92US715.6, JR-FL, TH14-12)
and C (93MW959). In the ﬁrst study, each group included
three NZW rabbits. In the second polyvalent formulations
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comparison study, each rabbit received either the DP6-001 or
the new polyvalent DNA prime followed by the boost of gp120
proteins matching the polyvalent gp120 immunogens used in
the DNA priming. In the second study, each group included
ﬁve NZW rabbits.
In both studies, rabbits received three DNA immunization at
Weeks 0, 2, and 4, followed with the protein boosts delivered at
Weeks 8 and 12. Sera were collected two weeks prior to the ﬁrst
immunization and two weeks after each animal immunization.
DNA vaccines were delivered by a Bio-Rad Helios gene gun
using 1-micron gold beads at a ratio of 2 mg of DNA per milli-
gram of gold beads. Each animal received 36 mg of DNA at
each immunization time point. For boost immunization, 50 mg
of gp120 proteins (10 mg for each gp120 protein) was diluted in
500 mL PBS and mixed with 500 mL Incomplete Freund’s Adju-
vant (IFA). The 1 mL adjuvanted protein solution was then
injected subcutaneously into the back of rabbits at multiple sites.
Enzyme linked immunosorbent assay (ELISA)
ELISA was run to detect gp120 protein or gp70-V1/V2 protein
speciﬁc IgG responses in 96 well microtiter plates as previous
described.4,8 Serial diluted rabbit immune sera were added to
plates coated with either gp120 or gp70-V1/V2 proteins, fol-
lowed by incubation with biotinylated anti-rabbit IgG and a
streptavidin horseradish peroxidase subsequently. For gp120
antigenicity analysis, the plates coated with various gp120 pro-
teins were incubated with Env-speciﬁc human mAbs at differ-
ent concentrations. Then the plates were incubated with
biotinylated anti-human IgG and a streptavidin horseradish
peroxidase subsequently.
The plates were ﬁnally developed for 3 min in 100 mL of a
3,305,50-tetramethylbenzidine substrate. The OD values were
read after stopping the reaction with 2N H2SO4. Endpoint titers
of rabbit sera were deﬁned as the last dilution of a serially
diluted serum sample with greater than double the background
optical density of a preimmune serum sample.
CD4bs-speciﬁc mAb b12 competitive binding assays
Competitive binding assays were performed as previously
described.48,49 JR-FL pseudovirus and Vesicular Stomatitis
Virus (VSV) glycoprotein were produced with the pSG3DEnv
backbone in 293T cells. Brieﬂy, after coating the microtiter
plates with 50 mL of mAb b12 at 5 mg/mL for 1 hr at room tem-
perature, the serially diluted rabbit sera was incubated with
pseudovirus correlating to 2.5 ng of p24/well for 1 hr. Then, the
virus/sera mixture was incubated on the ELISA wells for 3 hrs
at room temperature. Plates were then overlayed with 10,000
TZM-bl cells per well and incubated for 48 hrs at 37C. Lucifer-
ase activity was determined per the manufacturer’s instruction
(Promega). Data is reported as the serum dilution at which the
luciferase signal is reduced by 50% compared to a serum nega-
tive control.
HIV-1 neutralization assays
Two types of HIV-1 neutralization assays were performed in
this study. The ﬁrst neutralization assay (PhenoSense Assay,
Monogram, Inc) used recombinant viruses pseudotyped with
HIV-1 envelope proteins and a ﬁreﬂy luciferase indicator
gene.2,50,51 The panel of HIV-1 pseudoviruses included
three TCLA strains (MN, NL43 and SF162), and 13 primary
isolates including subtype A (92RW020 and 94UG103),
B (AC10.0.29, PVO.4, QH0692.42, SC422661.8, and JRCSF), C
(93IN905 and 98CN006), D (92UG046 and 94UG114), and AE
(92TH021 and CMU02). Rabbit sera elicited from either one
gp120 DNA prime – 5-valent protein boost, or 5-valent DNA
prime and 5-valent protein boost (DP6-001 or the new polyva-
lent formulation) were tested in this high throughput neutrali-
zation assay with starting serum dilution at 1:10. The rabbit
prebleed was used as the negative control and human HIV-1
infected patient serum N16 was used as the positive control.
Neutralizing activity was calculated as the percent inhibition of
viral replication (luciferase activity) at each antibody dilution
compared with the prebleed-negative control: % inhibition D
(1 – (luciferase C Ab/luciferase – Ab)) £ 100. The speciﬁcity
control was composed of a virus pseudotyped with an aMuLV
envelope. An HIV-serum combination was considered to have
positive neutralization if the inhibition of HIV was at least 50%
and >3X higher IC50 than the same plasmas tested with
aMuLV while the prebleed was not scored positive.
The second TZM-bl cell based neutralization assay was done
as previously described,6,11 either at Dr. Monteﬁori’s lab at
Duke University or in house at UMMS. The assays done at
Duke titrated the neutralizing antibody titers against HIV pseu-
doviruses from subtype B (SF162, MN, SS1196, 6536.3), C
(MW965) and AE (TH023.6). The in house neutralization
assays were done against a panel of 14 subtype B pseudoviruses
and 12 subtype C pseudoviruses as listed (Fig. 8), covering Tiers
1A, 1B, 2 and 3, using DP6-001 or new polyvalent immunized
rabbits at 1:10 serum dilution. Neutralization was calculated as
the percent change in luciferase activity in the presence of pre-
immune sera versus that of luciferase activity in the presence of
immune sera ((Preimmune RLUs – Immune RLUs)/(Preim-
mune RLUs))100.
ForteBio Octet QKe assay
The binding kinetics of mAbs to gp120 protein were studied
using a ForteBio Octet QKe instrument in a 96-well format
following the manufacturer’s instructions. Protein A coated
sensors (ForteBio) were loaded with Env-speciﬁc rabbit
mAbs R15 (C1), R20 (V3), R53 (C4) and R13 (C5), or pro-
tein G coated sensors were coated with IgG-CD4, Env-spe-
ciﬁc mAbs VRC01 (CD4bs), PGT128 (Glycan), 2G12
(Glycan) or 2158 (V2), at 10 mg/ml diluted in the kinetics
buffer (PBS/0.1%BSA/0.002%Tween 20). After capture, a 1-
min wash in loading buffer removed excess unbound Ab to
establish a new baseline signal. The biosensor tip was then
put into wells containing the selected gp120 proteins at
three-fold serially diluted concentrations from 100 to 11
nanomolar (nM), in loading buffer. The mAb-Env protein
association on-rate and off-rate were measured. KD values
were calculated as the ratio of off-rate/on-rate. The sensor-
grams were corrected with the blank reference and ﬁt with
the software ForteBio Data Analysis package 7.0 using a 1:1
binding model with the global ﬁtting function.
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Linear epitope mapping by peptide microarray
To map the linear epitope recognition in immune rabbit
sera, the rabbit sera collected at 2 weeks after the second
protein boost and pre-bleed as control were analyzed against
a library of HIV-1 Env linear peptides using JPT peptide
microarray as previously reported.52,53 Peptide libraries con-
sisting of 15-mers overlapped by 12 amino acids were
printed on glass slides, covering the full length of consensus
gp120 Env from HIV-1 group M consensus, subtypes A, B,
C, D and CRF01_AE including gp120 derived from vaccine
strains. Brieﬂy, the peptide microarray was performed using
a Tecan HS4000 Hybridization WorkStation. All arrays were
blocked with Superblock T20 PBS blocking buffer for
0.5 hour at 30C with heat inactivated plasma diluted 1:100
in SuperBlock T20. The arrays were incubated for 45
minutes at 30C with anti-IgG Cy5 secondary antibody (1.5
ug/ml ﬁnal concentration). PBS containing 0.1% Tween was
used for each of the washes between all steps. Arrays were
scanned at 635 nm using an Axon GenePix 4300 Scanner
(Molecular Devices, Sunnyvale, CA, USA) at a PMT setting
of 600, 50% laser power. Images were analyzed using Gene-
Pix Pro 7 software (Molecular Devices).
Bioinformatics analysis
The coverage percentages of monovalent, two-valent, three-val-
ent, four-valent, and ﬁve-valent gp120 matching current circu-
lating HIV-1 isolates, including Clade A1, A2, B, C, D, E, F1,
F2, G, H, AG, AB, BC, CD, BF and BG, were determined. The
heatmap of coverage percentage was constructed by JColorGrid
software54 with input gp120 protein sequences.
Statistical analyses
To analyze the statistical signiﬁcance of antibody responses
induced by different vaccination regimens, One Way ANOVA,
t-test and Fisher Exact tests were performed. The signiﬁcance
difference was considered when p < 0.05.
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